- M.D.: Columbia University College of Physicians and Surgeons
- Internship and Residency: Columbia-Presbyterian Medical Center
- Post–doctoral Fellowships: Brigham and Women’s Hospital, Rheumatology and Allergy and Immunology
Dr. Clifton Bingham is Professor of Medicine, Director of the Johns Hopkins Arthritis Center, Deputy Director for Research in the Division of Rheumatology, and Co-Director of the Rheumatic Diseases Research Core Center. He received his M.D. from Columbia University, where he also completed his Internal Medicine residency. He trained as a Fellow both in Rheumatology and in Allergy and Clinical Immunology at the Brigham and Women’s Hospital. Before coming to Hopkins in 2005, he was on faculty at NYU Hospital for Joint Diseases, where he founded a pioneering clinical and translational research center in rheumatology.
Dr. Bingham’s research experience has been diverse, from bench to bedside. His early work focused on understanding the cytokine regulation of inflammatory mediator generation operative in rheumatologic and allergic diseases. He has conducted prior translational research to better understand the role of initiating and amplifying pathways in rheumatoid arthritis, and has ongoing collaborations with several basic researchers to identify biomarkers for improved patient phenotyping and outcome prediction. He has served as principal investigator and helped to design and analyze a number of NIH and industry-sponsored clinical trials of multiple agents in early to late phases of development for rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. He has led several studies of the effects of biological and immunomodulatory therapies on responses to immunizations. He serves as a member of the Executive Leadership Committee for the international group Outcome Measures in Rheumatology (OMERACT), in which he works on efforts to develop, improve, and validate outcome measures, clinical trial methodology, and patient reported outcomes. He received three awards from the Patient Centered Outcomes Research Institute (PCORI) to study the implementation of patient reported outcomes in arthritis clinical care. Most recently his research has focused on the emerging rheumatic syndromes in patients receiving immune checkpoint inhibitors for cancer.